Influence of the American ODAC Statement on Austrian Bevacizumab Prescribing Practice for Metastatic Breast Cancer

BACKGROUND. Results of trial E2100 led to the accelerated approval of bevacizumab as first-line therapy for patients with metastatic breast cancer (MBC) in the U.S. in February 2008. Based on results from subsequent trials, the U.S. Food and Drug Administration Oncologic Drugs Advisory Committee (OD...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Preusser, Matthias, Fülöp, Gerhard, Berghoff, Anna Sophie, Heinzl, Harald, Steger, Guenther G., Greil, Richard, Zielinski, Christoph C., Bartsch, Rupert
Materialtyp: Artigo
Språk:Inglês
Publicerad: AlphaMed Press 2012
Ämnen:
European Perspectives
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3399659/
https://ncbi.nlm.nih.gov/pubmed/22744818
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0115
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk